Millennium Management’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-107,900
Closed -$7.11M – 5957
2026
Q1
$7.11M Buy
+107,900
New +$6.86M ﹤0.01% 2551
2024
Q2
– Sell
-18,300
Closed -$1.28M – 5992
2024
Q1
$1.28M Sell
18,300
-39,200
-68% -$3.03M ﹤0.01% 4089
2023
Q4
$4.8M Buy
+57,500
New +$2.08M ﹤0.01% 2823
2021
Q3
– Sell
-91,800
Closed -$1.82M – 6851
2021
Q2
$1.82M Buy
91,800
+45,200
+97% +$1.06M ﹤0.01% 4077
2021
Q1
$1.08M Buy
+46,600
New +$995K ﹤0.01% 4140

Other funds holding CYTK

Millennium Management's CYTK Position: Q3 2026 in Review

Millennium Management increased its Cytokinetics (CYTK) stake by 153% in Q3 2026, buying an estimated $12.8M and bringing the position to 277,135 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #1704.

Millennium Management first reported a position in CYTK in Q2 2013 and has held it in 50 quarters since. The position peaked at $100M in Q4 2023. 473 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Millennium Management held 277,135 shares of Cytokinetics worth $18.3M as of Q3 2026.
  • Millennium Management bought 167,418 Cytokinetics shares in Q3 2026, an estimated $12.8M.
  • Cytokinetics made up 0.01% of Millennium Management's portfolio in Q3 2026, its #1704 holding.
  • Millennium Management first reported a position in Cytokinetics in Q2 2013 and has held it in 50 quarters since.
  • Millennium Management's Cytokinetics position peaked at $100M in Q4 2023.
  • 473 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.